TE Connectivity plc Ordinary Shares vs Vir Biotechnology Inc. Common Stock — how do they compare? TE Connectivity plc Ordinary Shares trades at $210.29 (market cap $62.51B), while Vir Biotechnology Inc. Common Stock trades at $10.2 (market cap $1.80B). The key difference: TE Connectivity plc Ordinary Shares is far larger — about 34.7× Vir Biotechnology Inc. Common Stock's market cap, and TE Connectivity plc Ordinary Shares pays a 1.44% dividend while Vir Biotechnology Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold TE Connectivity plc Ordinary Shares for 0 Days and Vir Biotechnology Inc. Common Stock for 0 Days on average.
| TEL | VIR | |
|---|---|---|
Market Cap | $62.51B | $1.80B |
Volume | 2,249,319 | 1,782,836 |
Sector | Technology | Health |
52-Week High | $249.00 | $11.78 |
52-Week Low | $195.84 | $5.12 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $66.90B | $1.36B |
Dividend Yield | 1.44% | — |
Signals from Pluang's Aura AI — not financial advice
TE Connectivity (TEL) trades at $215.92, down 0.63% with a bullish technical outlook. The stock shows strong fundamentals with consistent earnings beats, 15.61% net margin, and improving cash flow. Recent analyst upgrades highlight growth potential as the company prepares for Q4 2026 earnings on October 28.
TEL offers solid investment appeal with 23.54% ROE and 48% analyst buy ratings, though near-term volatility may persist. The $253.22 consensus target implies 17% upside, supported by operational strength and dividend stability. Key risks include market sensitivity and execution challenges in competitive electronics components sector.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
TE Connectivity designs and manufactures connectivity and sensor solutions. Its products support transportation, energy networks, industrial automation, communications infrastructure, and medical technology.
Read more on TEL →Vir Biotechnology, Inc. is a US clinical-stage biopharmaceutical company that develops monoclonal antibody-based medicines to treat and prevent serious infectious diseases.
Read more on VIR →